OrthoPediatrics Corp. (KIDS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

OrthoPediatrics highlighted a roughly $1.6 billion U.S. TAM and about $3 billion globally, with its business split about 70% Trauma and Deformity correction and 30% Scoliosis. Management also noted its OPSB specialty bracing segment and a network of about 45 O&P clinics supporting pediatric orthopedic surgeons. The discussion was largely informational with no new financial results or guidance.

Analysis

The important takeaway is not the company’s current footprint, but the asymmetry created by a narrow category leader in a highly fragmented pediatric niche. A $1.6B U.S. addressable market with a 70/30 trauma/deformity-to-scoliosis mix implies the core growth engine is still dependent on surgeon conversion and implant pull-through, while the bracing/clinic layer can function as a distribution moat that lowers patient leakage and increases referral capture. That makes the business more resilient than a pure-device vendor, but also more operationally complex and easier for larger medtechs to attack indirectly through hospital contracting.

Second-order, the presence of clinics and specialty bracing changes the competitive game: it creates data, patient relationships, and post-op continuity that are hard to replicate quickly, but it also introduces reimbursement and execution risk that can compress margins if utilization softens. In a market this small, even modest share gains matter, so the real bull case is not unit growth alone but the compounding effect of installed surgeon relationships across multiple procedure types. The flip side is that if broader elective procedure volumes weaken, the clinic layer can become a drag rather than a stabilizer.

The contrarian read is that the market may be underestimating how slowly pediatric ortho adoption can scale versus adult medtech, because surgeon training, procedure standardization, and hospital value analysis cycles are long. That means the next 1-2 quarters are less about flashy TAM commentary and more about whether the company can keep converting surgeon loyalty into consistent utilization without needing outsized commercial spend. The key catalyst set is any evidence of accelerating cross-sell from trauma into scoliosis or from implants into bracing/clinic referrals; absent that, the name can look expensive relative to the pace of underlying penetration.

Key Decisions for Investors

• Stay structurally long KIDS on pullbacks over the next 3-6 months, but size modestly: the moat is real, yet the path to monetization is slow, so the risk/reward is better on weakness than at momentum highs.
• Pair trade: long KIDS / short a broader mid-cap medtech basket over 1-2 quarters if you want idiosyncratic growth exposure; the thesis is KIDS’ surgeon franchise and clinic ecosystem are less cyclical than generic procedure-volume names.
• If KIDS rallies on TAM rhetoric without evidence of accelerating mix or utilization, consider selling covered calls 1-2 quarters out to harvest volatility; the downside is slower-than-expected adoption rather than an immediate fundamental break.
• Watch for catalysts around clinic utilization and bracing attach rates; if those metrics inflect over the next 2 reporting cycles, add to the long because it would confirm the second-order network effect and de-risk margin durability.
• Avoid chasing a short here: the bear case is execution slippage, not structural commoditization, and a short needs a clear sign of slower surgeon conversion or reimbursement pressure before the payoff improves.